Results 211 to 220 of about 6,512,999 (388)

The Relationship between the Ionic Potentials of Salts and their Power of Inhibiting Lipolysis

, 1909
R.H. Nicholl
openalex   +1 more source

Immune checkpoint inhibitors in melanoma

The Lancet, 2021
M. Carlino, J. Larkin, G. Long
semanticscholar   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

Frontiers in Pharmacology, 2021
Yihui Zhou, Xiaomeng Gao, Meng Yuan, Bo Yang, Bo Yang, Qiaojun He, Qiaojun He, Qiaojun He, Ji Cao, Ji Cao, Ji Cao   +10 more
doaj   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience. [PDF]

Arthritis Res Ther
Yang J, Lee BW, Park Y, Ju JH, Kim WU, Park SH, Kwok SK, Lee JJ.   +7 more
europepmc   +1 more source

THE EFFECTS OF THE CARBONIC ANHYDRASE INHIBITOR “6063” ON ELECTROLYTES AND ACID-BASE BALANCE IN TWO NORMAL SUBJECTS AND TWO PATIENTS WITH RESPIRATORY ACIDOSIS 1 [PDF]

, 1953
Judith Nadell, Helen Kalinsky
openalex   +1 more source

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Journal of the American College of Cardiology, 2018
Syed S Mahmood, M. Fradley, J. Cohen, A. Nohria, K. Reynolds, L. Heinzerling, R. Sullivan, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta, M. Kirchberger, Magid Awadalla, Malek Z O Hassan, J. Moslehi, Sachin P. Shah, Sarju Ganatra, P. Thavendiranathan, D. Lawrence, J. Groarke, T. Neilan   +19 more
semanticscholar   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source